Pharmacology of NSAIDs (Non-Steroidal Anti-Inflammatory Drugs (Dr. Sohail Ahmad)
Clinical Pharmacology of A nti-inflammatory Agents
-
Upload
catalina-amora -
Category
Documents
-
view
37 -
download
0
description
Transcript of Clinical Pharmacology of A nti-inflammatory Agents
![Page 1: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/1.jpg)
Clinical Pharmacology of Anti-inflammatory Agents
![Page 2: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/2.jpg)
RHEUMATIC DISEASES
Rheumatic diseases (rheumatism) are painful conditions that affect millions. These diseases cause inflammation, swelling, and pain in the joints or muscles.
Some rheumatic diseases like osteoarthritis are the result of "wear and tear" to the joints. Other rheumatic diseases, such as rheumatoid arthritis, happen when the immune system goes haywire; the immune system attacks the linings of joints, causing joint pain, swelling, and destruction.
![Page 3: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/3.jpg)
Fibromyalgia
![Page 4: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/4.jpg)
Osteoarthritis
![Page 5: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/5.jpg)
Rheumatoid ArthritisRA is sometimes called a crippling disease. That's because it
can result in permanent joint damage and deformity.
RA signs and symptoms include: Joint pain, stiffness, and swelling Involvement of multiple joints (symmetrical pattern) Other organ involvement Joint stiffness, especially in the morning Fatigue Fevers Lumps called rheumatoid
nodules To diagnose RA, doctor will ask about medical history and do
a physical examination. Also, X-rays and blood tests will likely be taken. One blood test may be for rheumatoid factor; it is positive in 70% to 80% of those with RA.
![Page 6: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/6.jpg)
![Page 7: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/7.jpg)
Rheumatoid Arthritis
![Page 8: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/8.jpg)
Systemic lupus erythematosus
![Page 9: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/9.jpg)
Ankylosing Spondylitis
![Page 10: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/10.jpg)
![Page 11: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/11.jpg)
Sjogren's Syndrome
Venus Williams Diagnosed With Sjogren’s Syndrome
![Page 12: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/12.jpg)
![Page 13: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/13.jpg)
Therapeutic Strategies
The treatment of patients with inflammation involves two primary goals: first, the relief of symptoms and the maintenance of function, which are usually the major continuing complaints of the patient; and second, the slowing or arrest of the tissue-damaging process.
![Page 14: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/14.jpg)
NSAIDs can be classified based on their chemical structure or mechanism of action
Salicylates Aspirin (acetylsalicylic acid) Diflunisal Salsalate
![Page 15: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/15.jpg)
NSAIDsPropionic acid derivatives Ibuprofen Naproxen Fenoprofen Ketoprofen Flurbiprofen Oxaprozin Acetic acid derivatives Indomethacin Sulindac Etodolac Ketorolac Diclofenac (Safety alert by FDA) Nabumetone
![Page 16: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/16.jpg)
NSAIDsEnolic acid (Oxicam) derivatives Piroxicam Meloxicam Tenoxicam Droxicam Lornoxicam Isoxicam Fenamic acid derivatives( Fenamates ) Mefenamic acid Meclofenamic acid Flufenamic acid Tolfenamic acid
![Page 17: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/17.jpg)
NSAIDsSelective COX-2 inhibitors (Coxibs) Celecoxib (FDA alert) Rofecoxib (withdrawn from market) - increased cardiovascular
thrombotic events Valdecoxib (withdrawn from market) - increased cardiovascular
thrombotic events Parecoxib FDA withdrawn Lumiracoxib TGA cancelled registration Etoricoxib FDA withdrawn Firocoxib used in dogs and horses Sulphonanilides Nimesulide (systemic preparations are banned by several countries for
the potential risk of hepatotoxicity) Others Licofelone acts by inhibiting LOX (lipooxygenase) & COX and hence
known as 5-LOX/COX inhibitor
![Page 18: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/18.jpg)
InflammationThe cell damage associated with inflammation acts on cell membranes to cause leukocytes to release lysosomal enzymes; arachidonic acid is then liberated from precursor compounds, and various eicosanoids are synthesized. The cyclooxygenase (COX) pathway of arachidonate metabolism produces prostaglandins, which have a variety of effects on blood vessels, on nerve endings, and on cells involved in inflammation. The lipoxygenase pathway of arachidonate metabolism yields leukotrienes, which have a powerful chemotactic effect on eosinophils, neutrophils, and macrophages and promote bronchoconstriction and alterations in vascular permeability.
![Page 19: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/19.jpg)
Cyclooxygenase isoforms
The discovery of two cyclooxygenase isoforms (COX-1 and COX-2) led to the concept that the constitutive COX-1 isoform tends to be homeostatic in function, while COX-2 is induced during inflammation and tends to facilitate the inflammatory response. On this basis, highly selective COX-2 inhibitors have been developed and marketed on the assumption that such selective inhibitors would be safer than nonselective COX-1 inhibitors but without loss of efficacy.
![Page 20: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/20.jpg)
The more an NSAID blocks COX-1, the greater is its tendency to cause ulcers and promote bleeding. But celecoxib (Celebrex), blocks COX-2 and has little effect on COX-1, and is therefore further classified as a selective COX-2 inhibitor. Selective COX-2 inhibitors cause less bleeding and fewer ulcers than other NSAIDs.
![Page 21: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/21.jpg)
![Page 22: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/22.jpg)
NSAIDs are generally indicated for the symptomatic relief of the following conditions:
Rheumatoid arthritis Osteoarthritis Inflammatory arthropathies (e.g. ankylosing spondylitis, psoriatic
arthritis, Reiter's syndrome) Acute gout Dysmenorrhoea (menstrual pain) Metastatic bone pain Headache and migraine Postoperative pain Mild-to-moderate pain due to inflammation and tissue injury Pyrexia (fever) Ileus Renal colic They are also given to neonate infants whose ductus arteriosus is
not closed within 24 hours of birth Aspirin, the only NSAID able to irreversibly inhibit COX-1, is also
indicated for inhibition of platelet aggregation.
![Page 23: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/23.jpg)
Complications of NSAIDsNSAIDs are safe drugs. However, they have many side effects. The side effects happen more often when they are used over long periods of time, which is common in arthritis patients. Some of the side effects can become very serious. Central nervous system: Headaches, tinnitus, and
dizziness. Cardiovascular: Fluid retention hypertension,
edema, and rarely, congestive heart failure. Gastrointestinal: Abdominal pain, dysplasia, nausea,
vomiting, and rarely, ulcers or bleeding. Hematologic: Rare thrombocytopenia, neutropenia,
or even aplastic anemia. Hepatic: Abnormal liver function tests and rare liver
failure. Pulmonary: Asthma. Rashes: All types, pruritus. Renal: Renal insufficiency, renal failure,
hyperkalemia, and proteinuria.
![Page 24: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/24.jpg)
Choice of NSAID
All NSAIDs, including aspirin, are about equally efficacious with a few exceptions—tolmetin seems not to be effective for gout, and aspirin is less effective than other NSAIDs (eg, indomethacin) for ankylosing spondylitis.
Thus, NSAIDs tend to be differentiated on the basis of toxicity and cost-effectiveness. For example, the gastrointestinal and renal side effects of ketorolac limit its use. Some surveys suggest that indomethacin or tolmetin are the NSAIDs associated with the greatest toxicity, while salsalate, aspirin, and ibuprofen are least toxic. The selective COX-2 inhibitors were not included in these analyses.
![Page 25: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/25.jpg)
Choice of NSAID (cont’d) For patients with renal insufficiency, nonacetylated salicylates may
be best. Diclofenac and sulindac are associated with more liver function test abnormalities than other NSAIDs. The relatively expensive, selective COX-2 inhibitor celecoxib, is probably safest for patients at high risk for gastrointestinal bleeding but may have a higher risk of cardiovascular toxicity. Celecoxib or a nonselective NSAID plus omeprazole or misoprostol may be appropriate in patients at highest risk for gastrointestinal bleeding; in this subpopulation of patients, they are cost-effective despite their high acquisition costs.
The choice of an NSAID thus requires a balance of efficacy, cost-effectiveness, safety, and numerous personal factors (eg, other drugs also being used, concurrent illness, compliance, medical insurance coverage), so that there is no best NSAID for all patients. There may, however, be one or two best NSAIDs for a specific person.
![Page 26: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/26.jpg)
CORTICOSTEROIDS Most of the known effects of the glucocorticoids
are mediated by widely distributed glucocorticoid
receptors
![Page 27: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/27.jpg)
CORTICOSTEROIDS
![Page 28: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/28.jpg)
Glucocorticoids. Anti-Inflammatory and Immunosuppressive effects Glucocorticoids cause vasoconstriction when applied
directly to the skin, possibly by suppressing mast cell degranulation. They also decrease capillary permeability by reducing the amount of histamine released by basophils and mast cells.
The anti-inflammatory and immunosuppressive effects of glucocorticoids are largely due to the actions described above. In humans, complement activation is unaltered, but its effects are inhibited. Antibody production can be reduced by large doses of steroids, although it is unaffected by moderate doses (eg, 20 mg/d of prednisone).
![Page 29: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/29.jpg)
![Page 30: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/30.jpg)
Uses of Corticosteroids
The most commonly used corticosteroids are prednisone, prednisolone, and methylprednisolone. Corticosteroids can be given orally or put directly into the bloodstream through an intravenous needle. They can also be injected directly into an inflamed spot. Corticosteroid cream can be rubbed on the skin.
Corticosteroids are powerful drugs. But they are also highly toxic. Doctors have different opinions about how corticosteroids should be used.
Corticosteroids can't cure a disease. But they do seem to affect the development of some diseases, including rheumatoid arthritis (RA).
![Page 31: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/31.jpg)
Some Commonly Used Natural and Synthetic Corticosteroids for General Use
Short- to medium-acting glucocorticoids:
Hydrocortisone (cortisol)
Cortisone
Prednisone
Prednisolone
Methylprednisolone
![Page 32: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/32.jpg)
Some Commonly Used Natural and Synthetic Corticosteroids for General Use
Intermediate-acting glucocorticoids
Triamcinolone
Paramethasone
Fluprednisolone Long-acting glucocorticoids
Betamethasone
Dexamethasone
![Page 33: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/33.jpg)
CORTICOSTEROIDS
![Page 34: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/34.jpg)
Withdrawal
When stop taking corticosteroids, the doses will be slowly reduced over a period of days or weeks. Even if patient has only been taking steroids for a few weeks, he will still need to taper off. Corticosteroid withdrawal can be very difficult for body. In many patients, the disease symptoms become worse. Some people experience a sickness that includes fevers, nausea, vomiting, low blood pressure, and low blood sugar. Others have withdrawal symptoms that include muscle and joint pain, weight loss, fever, and headaches. If patient have problems coming off corticosteroids, doctor will have taper off the drug more slowly.
Different people, and different diseases, react very differently to corticosteroids.
![Page 35: Clinical Pharmacology of A nti-inflammatory Agents](https://reader033.fdocuments.us/reader033/viewer/2022042608/568134b6550346895d9bd527/html5/thumbnails/35.jpg)
Choosing the right DMARDCurrent evidence suggests that combinations of
DMARDs are more effective, and probably less toxic, than monotherapy. Methotrexate is often used as an anchor drug, combined with hydroxychloroquine, sulfasalazine or leflunomide. An anti-TNF-alpha drug such as etanercept or infliximab may also be used in combination. There is a stronger evidence base for the disease-modifying effects of methotrexate, sulfasalazine, leflunomide and intramuscular gold than for hydroxychloroquine, penicillamine, oral gold, ciclosporin or azathioprine, although these agents do improve symptoms and some objective measures of inflammation. The choice of first agent or combination of agents should be based on a risk/benefit analysis for individual patients.